Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

The search for effective Alzheimer’s treatments is emerging as a promising market, capturing the attention of major ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

According to BMO Capital Markets, Medicare coverage of Lilly’s Zepbound opens the door to using secondary indications to ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things to look for include more widespread adoption of artificial intelligence ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...